These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21570299)

  • 1. Expression of leukemia inhibitory factor in the cerebrospinal fluid of patients with multiple sclerosis.
    Mashayekhi F; Salehi Z
    J Clin Neurosci; 2011 Jul; 18(7):951-4. PubMed ID: 21570299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis.
    Fainardi E; Castellazzi M; Tamborino C; Trentini A; Manfrinato MC; Baldi E; Tola MR; Dallocchio F; Granieri E; Bellini T
    Mult Scler; 2009 May; 15(5):547-54. PubMed ID: 19318509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.
    Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET
    Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis.
    Verbeek MM; Notting EA; Faas B; Claessens-Linskens R; Jongen PJ
    Acta Neurol Scand; 2010 May; 121(5):309-14. PubMed ID: 19925532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis.
    Moreira MA; Tilbery CP; Monteiro LP; Teixeira MM; Teixeira AL
    Acta Neurol Scand; 2006 Aug; 114(2):109-13. PubMed ID: 16867033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum and CSF PDGF-AA and FGF-2 in relapsing-remitting multiple sclerosis: a case-control study.
    Harirchian MH; Tekieh AH; Modabbernia A; Aghamollaii V; Tafakhori A; Ghaffarpour M; Sahraian MA; Naji M; Yazdankhah M
    Eur J Neurol; 2012 Feb; 19(2):241-7. PubMed ID: 21771201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis.
    Tumani H; Lehmensiek V; Rau D; Guttmann I; Tauscher G; Mogel H; Palm C; Hirt V; Suessmuth SD; Sapunova-Meier I; Ludolph AC; Brettschneider J
    Neurosci Lett; 2009 Mar; 452(2):214-7. PubMed ID: 19383442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis.
    Sriram S; Stratton CW; Yao S; Tharp A; Ding L; Bannan JD; Mitchell WM
    Ann Neurol; 1999 Jul; 46(1):6-14. PubMed ID: 10401775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis.
    Rentzos M; Cambouri C; Rombos A; Nikolaou C; Anagnostouli M; Tsoutsou A; Dimitrakopoulos A; Triantafyllou N; Vassilopoulos D
    J Neurol Sci; 2006 Feb; 241(1-2):25-9. PubMed ID: 16316662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis.
    Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Tamborino C; Paolino E; Tola MR; Granieri E; Baricordi OR
    Mult Scler; 2008 May; 14(4):446-54. PubMed ID: 18208868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased prevalence of and gene transcription by Chlamydia pneumoniae in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis.
    Dong-Si T; Weber J; Liu YB; Buhmann C; Bauer H; Bendl C; Schnitzler P; Grond-Ginsbach C; Grau AJ
    J Neurol; 2004 May; 251(5):542-7. PubMed ID: 15164186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of IFN-beta, leptin and simvastatin on LIF secretion by T lymphocytes of MS patients and healthy controls.
    Vanderlocht J; Hendriks JJ; Venken K; Stinissen P; Hellings N
    J Neuroimmunol; 2006 Aug; 177(1-2):189-200. PubMed ID: 16797728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum and cerebrospinal fluid prolactin levels in male and female patients with clinically-isolated syndrome or relapsing-remitting multiple sclerosis.
    Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Sfagos C
    J Neuroendocrinol; 2010 Jun; 22(6):503-8. PubMed ID: 20236233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis.
    Scalabrino G; Galimberti D; Mutti E; Scalabrini D; Veber D; De Riz M; Bamonti F; Capello E; Mancardi GL; Scarpini E
    Brain Res; 2010 May; 1333():64-71. PubMed ID: 20347721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss.
    Butzkueven H; Emery B; Cipriani T; Marriott MP; Kilpatrick TJ
    Glia; 2006 May; 53(7):696-703. PubMed ID: 16498619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis.
    Martínez-Yélamos A; Saiz A; Bas J; Hernandez JJ; Graus F; Arbizu T
    Neurosci Lett; 2004 Jun; 363(1):14-7. PubMed ID: 15157986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair.
    Marriott MP; Emery B; Cate HS; Binder MD; Kemper D; Wu Q; Kolbe S; Gordon IR; Wang H; Egan G; Murray S; Butzkueven H; Kilpatrick TJ
    Glia; 2008 Apr; 56(6):686-98. PubMed ID: 18293407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of antibody reactivity in paired cerebrospinal fluid and serum of a relapsing remitting multiple sclerosis patient.
    Govarts C; Somers K; Hupperts R; Stinissen P; Somers V
    Autoimmunity; 2009; 42(8):699-704. PubMed ID: 19835487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.
    Khademi M; Kockum I; Andersson ML; Iacobaeus E; Brundin L; Sellebjerg F; Hillert J; Piehl F; Olsson T
    Mult Scler; 2011 Mar; 17(3):335-43. PubMed ID: 21135023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
    Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.